|
|
 |
Customer References in Life Sciences
Image analysis is fundamental to every stage of the drug development cycle. The task falls largely to experts in a specific therapeutic area who draw on their experience, but the process is slow and, to a considerable degree, subjective. For many years, there has been a great need for an effective automated image analysis solution.
Autoted image analysis systems must be able to handle low signal/noise ratio images, spectral deviations within and between images, experimental variations and ‘biological noise’ – the inherent variability of living organisms. They must be able to compare structures on different scales, classify regions of interest and identify and measure units of interest correctly. Modern image analysis systems should support digital pathology and new drug development methods such as high-content screening. Each one of these tasks is far from trivial; taken together they are an immense challenge.
Definiens image analysis platform is used across the entire lifecycle of drug development, helping bioscience and pharmaceutical companies to analyze vast numbers of images quickly, accurately and consistently. Definiens supports their research and development programs, bringing them insights that speed up drug development and decrease late stage attrition.
Of the 20 largest pharmaceutical companies in the world, 16of them are already Definiens' customers. So too are many bioscience companies and research institutions in US and Europe:
|
Affiris GmbH
|
 |
www.affiris.com
|
“The Definiens Enterprise Image Intelligence Suite is an open platform that can be easily integrated with the existing hardware as well as image acquisition devices and software. It enables even untrained users to calibrate and execute versatile image analysis workflows [...]”
Dr. Markus Mandler, Head of Neurodegeneration Department at Affiris
|
 Press Release
|
Altana Pharma AG
|
 |
www.altanapharma.com |
“Definiens’ technology underpins ALTANA’s move towards integrated image assessment which will advance even further now that ALTANA belongs to the new NYCOMED organization.”
Prof. Germann, Head of IPAS (Institut für Präklinische Arzneimittelsicherheit)
|
 Case Study
Case Study
Press Release
|
AstraZeneca
|
 |
www.astrazeneca.com |
"We are using Definiens Developer to analyze fluorescently stained images. The Thumbnail View and the Swipe View that come with version 7 have been saving us a lot of time. The new pre-processing algorithms and pixelfilters enable us to process pixellayers upfront. This means that we can identify the relevant structures easier and faster."
Dr. Jo Peel, Senior Scientist, AstraZeneca
|
 Scientific Poster
 Application Note
Application Note
Press Release
|
| Cenix BioScience |
 |
www.cenix-bioscience.com/ |
“After we tested and reviewed the available high content screening software, it became obvious that there is no other solution out there that can support us in the extremely challenging image analysis tasks we perform for our customers.”
Dr. Michael Hannus, Group Leader, Cell-based Discovery & Validation, Cenix BioScience
|
Press Release
Press Release
|
| Max Planck Institute of Molecular Cell Biology and Genetics in Dresden |
| |
www.mpi-cbg.de |
“Definiens has opened up new worlds of opportunities for performing screens utilizing assays that have previously been impossible to accommodate in high throughput screens due to the lack of refined software for automated image analysis and data extraction.”
Dr. Ivan Baines, Scientific Coordinator and Director of Services and Facilities at MPI-CBG |
Case Study
|
| Montpellier Rio Imaging |
 |
www.mri.cnrs.fr/ |
“Definiens solutions will play a decisive role in MRI continuous efforts for the development of new services in biological imaging."
Chief Manager Dr. Pierre Travo, at Montpellier RIO Imaging |
Press Release
|
| Novartis Pharma AG |
 |
www.novartis.com |
“Definiens solved our problem of automatically detecting small intestine crypts and counting proliferating and non-proliferating cells which was not possible with any other software solution.”
Dr. Elke Persohn, Head of the Cellular Imaging Group, at Novartis Pharma AG |
Case Study
Scientific Poster
Scientific Paper
|
| Servier |
 |
www.servier.com
|
“In order to put molecular histopathology at the core of Servier’s drug discovery programs, the decision to integrate Definiens’ innovative and robust Definiens Enterprise Image Intelligence™ Suite is a critical step in the success of this strategy.”
Brian Lockhart, Director Molecular Pharmacology and Pathophysiology at Servier |
Press Release
|
|
